Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Urovant Sciences Ltd

(NASDAQ: UROV)
Add to Portfolio
+0.58 (+6.08%)
as of Sep 20, 2019

Urovant Sciences Parent Company, Roivant Sciences, and

BusinessWire via COMTEX - Fri Sep 06, 09:00AM EDT
Urovant Sciences (Nasdaq: UROV) today announced that its parent company, Roivant Sciences, and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506), a leading global Japanese pharmaceutical company, have entered into a non-binding memo(full story)
UROV: 10.12 (+0.58)

Urovant Sciences Appoints James Robinson to its Board

BusinessWire via COMTEX - Wed Mar 06, 08:00AM EST
Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced James Robinson, President and(full story)
UROV: 10.12 (+0.58), ALKS: 21.20 (-0.02)